Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Sigma-Aldrich Launches Breakthrough Genome-Editing Tools

Published: Wednesday, September 17, 2008
Last Updated: Wednesday, September 17, 2008
Bookmark and Share
CompoZr™ Zinc Finger Nuclease platform of reagents enables permanent and heritable modification of the genome.

Sigma-Aldrich has launched its CompoZr™ platform of zinc finger nuclease (ZFN) reagents. The CompoZr ZFN platform of reagents is expected to provide researchers with the ability to target and manipulate the genome of living cells, resulting in cell lines or whole organisms with defined gene deletions, insertions, or corrections.

Initially offered as a customized service for developing ZFNs for specific gene targets, the CompoZr ZFN platform will eventually include ZFN-based kits for targeted transgene insertion and a catalog of off-the-shelf reagents for commonly studied gene targets, gene families, and pathways.

Applications for Sigma's new platform technology include creation of knockout and knock-in cell lines, cell lines that yield significantly greater amounts of protein, and novel transgenic animal models.

ZFN reagents are a class of engineered DNA-binding proteins that facilitate targeted editing of the genome within a living cell by creating double-strand breaks in DNA at user-specified locations. Double-strand breaks stimulate the cell's natural DNA-repair processes, namely homologous recombination and non-homologous end joining, to induce site-specific mutagenesis.

Using CompoZr reagents, researchers can, for the first time, generate targeted genomic edits using a single-step procedure, resulting in cell lines with permanent and heritable gene deletions, insertions, or modifications.

Additionally, Sigma-Aldrich is collaborating with leading academic researchers to demonstrate the effectiveness of ZFNs in the creation of whole animal knockout models in mice and other species, including rats and rabbits.

"Zinc Finger Nuclease technology has held significant promise for more than a decade and is now mature enough to fundamentally alter the way in which research on living cells and organisms is conducted," said Dr. David Smoller, President of Sigma-Aldrich's Research Biotech Business Unit. "By refining ZFN production methods and utilizing our established distribution capabilities, Sigma-Aldrich is making this exciting technology available to life science researchers worldwide."

By facilitating the creation of complete gene knockout and knock-in somatic, embryonic and primary cell lines, ZFNs allow researchers to precisely determine the biological function of a gene in more relevant backgrounds. It is anticipated that ZFN-mediated genome editing could be used to generate novel animal models of disease that more closely mimic human disease, as well as providing more realistic data on the potential toxicity of new drug compounds.

For biopharmaceutical manufacturers, ZFNs will enable the creation of cell lines with improved growth characteristics, altered glycosylation properties, and other traits resulting in higher yields.

Through its exclusive partnership with Sangamo BioSciences, Inc., Sigma Life Science is the sole source of validated research reagents incorporating ZFN technology. Sigma Life Science employs high-throughput production methods to create customized ZFN reagents for user-specified gene targets in just six to eight weeks.

All CompoZr reagents are functionally validated in a cell line appropriate for the intended organism of interest, and customers are provided with full protocols for use of their reagents and troubleshooting support from Sigma Life Science's experienced technical team.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SAFC Completes Manufacturing Expansion in St. Louis
Expansion to support commercial-scale antibody drug conjugate (ADC) manufacturing.
Saturday, May 16, 2015
SAFC Expands Carlsbad, Calif. Facility
Expansion to support commercial-scale gene therapy production, testing and filling.
Saturday, May 16, 2015
Sigma-Aldrich Expands in Singapore
New State-of-the-Art Technical Center, cGMP Distribution Center and Headquarters enhances ability to support customers in the region.
Monday, April 20, 2015
Sigma-Aldrich & Roche Enter Exclusive Distribution Agreement
Provides researchers with global access to Roche biochemical reagents product portfolio.
Thursday, March 19, 2015
Sigma and Czech Center for Phenogenomics Collaborate
Sigma-Aldrich® and the Institute of Molecular Genetics, Czech Center for Phenogenomics, establish CRISPR core lab collaboration.
Friday, January 30, 2015
SAFC’s Dry Powder Media Manufacturing Facility in Irvine, Scotland
Officially opens following extensive validation process.
Friday, January 23, 2015
Sigma-Aldrich Licenses Foundational CRISPR Patents from Broad Institute
Company is able to make, use and distribute the advanced gene editing tools for numerous research applications.
Tuesday, December 09, 2014
Sigma-Aldrich to Restructure Business into Three New Units
Sigma-Aldrich has provided the first details of a major restructuring that will align its organisation into three customer and market-focused business units.
Thursday, November 22, 2012
SAGE® Labs, Ekam Imaging, Inc. Partner on Preclinical Imaging Assays
Companies to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam's expertise in functional magnetic resonance imaging (fMRI) technology.
Friday, October 19, 2012
Sigma-Aldrich to Acquire BioReliance
Sigma-Aldrich Corporation has signed an agreement to acquire BioReliance Holdings, Inc. from Avista Capital Partners for $350 million in cash.
Tuesday, January 10, 2012
Biotech firm inks deal with Sigma-Aldrich
Henrietta-based biotechnology company Diffinity Genomics Inc. has inked a non-exclusive global distribution deal with Sigma-Aldrich Co. LLC, the local company said.
Wednesday, November 30, 2011
Hydrogen Storage Collaboration Between Sigma-Aldrich and Ilika Technologies to Scale-up and Commercialize Boron Hydride Materials
Materials show promise as high energy, low pressure hydrogen source.
Monday, July 25, 2011
Domainex Collaborates with Sigma-Aldrich to Advance the Study of Epigenetic Proteins Involved in Cancer and Stem Cell Biology
Domainex Ltd., have announced a collaboration with Sigma-Aldrich that will provide essential tools, including biochemical assays and monoclonal antibodies, for the study of proteins involved in the rapidly developing field of epigenetics.
Monday, November 15, 2010
Sigma® Life Science to Supply Oligonucleotides to Research Councils UK
A three-year contract with RCUK Shared Services Centre Limited to be a preferred supplier for synthetic oligonucleotides.
Monday, September 20, 2010
Sigma-Aldrich® Receives National Institutes of Health Funding for Cardiovascular Disease Research
Sigma® Life Science to analyze plasma samples from FHS in researching novel biomarkers for cardiovascular disease.
Monday, August 09, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos